Investors have a few months at most to benefit from this remarkable opportunity.
With Phase 3 trials about to begin and success all but assured; liver protocols and trails not far off which will bring the deal with China's SinoPharm and other countries, Combo trials will quickly follow - the concrete data will prove it's safety and remarkable efficacy compared to approved and developing therapies. Trials are likely to be stopped early because of the vast difference in results between arms of the trials. Then a Big Pharma will have to step up with a buy-out offer. Patients and investors will benefit greatly.
Add a comment...